Key Highlights

  • Akebia Therapeutics shares closed down 26% at $0.95.
  • Q2 revenue of $49.1 million fell 21% year-over-year.
  • Vafseo sales surged 60%, but Auryxia revenue slumped 46% due to generic entrants.
  • The company reported a net loss of $8.9 million.

Akebia Therapeutics, Inc. (NASDAQ: AKBA) shares closed down 26% at $0.95 after the company disclosed second-quarter revenue of $49.1 million, a 21% year-over-year decrease, as a 60% surge in Vafseo sales was overshadowed by a 46% slump in Auryxia revenue due to generic entrants.

What Happened

Despite a net loss of $8.9 million, the firm emphasized Vafseo's momentum with over 10,500 patients and encouraging Phase 4 VOICE trial data.

Market Reaction

Shares fell sharply as investors focused on the scale of the overall revenue decline driven by generic competition to Auryxia, even as Vafseo showed strong growth momentum.

Outlook

The company's $155.5 million cash reserve is projected to support at least two years of operations, providing runway as Vafseo's growth is weighed against continued Auryxia erosion from generic competition.

Why did Akebia Therapeutics shares fall 26%?

Shares fell after overall Q2 revenue declined 21% year-over-year, as a 46% slump in Auryxia revenue from generic competition overshadowed 60% growth in Vafseo sales.

How many patients are now on Vafseo?

Over 10,500 patients.

How long can Akebia's cash reserve support operations?

The $155.5 million cash reserve is projected to support at least two years of operations.